Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Commentary

The harms of benzodiazepines for patients with dementia

Paula A. Rochon, Nicholas Vozoris and Sudeep S. Gill
CMAJ April 10, 2017 189 (14) E517-E518; DOI: https://doi.org/10.1503/cmaj.170193
Paula A. Rochon
Women’s College Research Institute (Rochon), Women’s College Hospital; Department of Medicine (Rochon, Vozoris), Institute of Health Policy, Management, and Evaluation (Rochon), University of Toronto; Department of Medicine and Keenan Research Centre in the Li Ka Shing Knowledge Institute (Vozoris), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Gill), Queen’s University; Institute for Clinical Evaluative Sciences (Gill), Kingston, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paula.rochon@wchospital.ca
Nicholas Vozoris
Women’s College Research Institute (Rochon), Women’s College Hospital; Department of Medicine (Rochon, Vozoris), Institute of Health Policy, Management, and Evaluation (Rochon), University of Toronto; Department of Medicine and Keenan Research Centre in the Li Ka Shing Knowledge Institute (Vozoris), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Gill), Queen’s University; Institute for Clinical Evaluative Sciences (Gill), Kingston, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudeep S. Gill
Women’s College Research Institute (Rochon), Women’s College Hospital; Department of Medicine (Rochon, Vozoris), Institute of Health Policy, Management, and Evaluation (Rochon), University of Toronto; Department of Medicine and Keenan Research Centre in the Li Ka Shing Knowledge Institute (Vozoris), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Gill), Queen’s University; Institute for Clinical Evaluative Sciences (Gill), Kingston, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

See related article at www.cmaj.ca/lookup/doi/10.1503/cmaj.160126

A wide spectrum of neuropsychiatric symptoms may develop in people with dementia. These symptoms can cause distress to families and caregivers and are challenging for clinicians to manage. Symptoms range from physical aggression to wandering and sleep disturbances. Although a drug therapy that could resolve them without causing new problems would be welcome, no such drug currently exists; serious adverse events often offset the modest benefits of psychotropic drugs in this setting. In the absence of predictably safe and effective drug therapies to manage these challenging behaviours, clinicians are wise to remember the maxim “first do no harm.”

Clinicians usually avoid prescribing benzodiazepines for older people with dementia because these drugs are associated with well-documented harms, including fall-related injuries such as fractures.1 They are also associated with cognitive worsening,2 an adverse event that is especially concerning in vulnerable older individuals who already have cognitive deficits. In a linked research study, Taipale and colleagues3 used Finnish administrative data to explore further the potential harm of benzodiazepines or benzodiazepine-related drugs (the so-called Z-drugs, which include zopiclone and zolpidem) in people with dementia.

Despite known harms, benzodiazepines continue to be used for a variety of conditions, including the management of neuropsychiatric symptoms associated with dementia. Canadian data show that the rate of benzodiazepine use is 15% in the community; the rate increases to more than 30% in long-term care facilities,4 where at least half of residents aged 80 years and older have dementia.5 A recent study found that women were more likely than men to receive potentially inappropriate prescriptions, particularly for benzodiazepines and other hypnotics.6 Another study showed that benzodiazepine therapy was continued chronically in more than 1% of older adults following a hospital admission.7

Taipale and colleagues focus on use of benzodiazepines or Z-drugs in patients with newly diagnosed Alzheimer disease living in the community. The authors report that use of these drugs was associated with a modest increased risk in the development of pneumonia severe enough to result in hospital admission or death (adjusted hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.05–1.42). The risk of pneumonia appeared highest within the first 30 days of drug use. Although use of benzodiazepines and Z-drugs collectively was associated with a statistically significant increased risk of pneumonia, Z-drug use alone was not (adjusted HR 1.10, 95% CI 0.84–1.44). This lack of statistical significance for the association between Z-drugs and pneumonia may reflect limited power of the study, given the overall modest risk observed.

The findings reported in the linked study suggest that pneumonia should be added to the list of potential harms associated with use of benzodiazepines and Z-drugs in people with dementia. Although a nonsignificant trend for pneumonia in association with use of the Z-drugs was reported, a previous large, population-based study showed that pneumonia risk extended to use of these drugs.8 Thus, further study is warranted to determine the comparative safety of benzodiazepines and Z-drugs.

Pneumonia is common in patients with dementia, particularly those with advanced dementia.9 There are several mechanisms that support the link between benzodiazepine use and pneumonia. For example, these medications produce sedation (leading to hypoventilation), can reduce pressure in the lower esophageal sphincter (leading to reflux and aspiration), and can suppress immune function, all of which may contribute to pneumonia risk.10 Benzodiazepine exposure has been associated with pneumonia risk in other populations, including people with chronic obstructive pulmonary disease.11

Taipale and colleagues acknowledge that the association they found between benzodiazepine and Z-drug use and pneumonia was relatively modest. However, there are reasons that this association may have been underestimated in the study. First, the authors identified only pneumonia severe enough to result in hospital admission or death. They excluded cases of pneumonia that were less severe and treated in outpatient settings or through an emergency department visit. Second, the authors did not include older adults with dementia living in long-term care facilities. Residents in such facilities mainly comprise older women, and a substantial proportion has dementia; this vulnerable group is at particularly high risk of pneumonia. Further valuable insights would be gained through future studies of the association between benzodiazepines and pneumonia that consider a wider spectrum of ways in which pneumonia is diagnosed and managed in a range of care settings. As such, population-level data could provide opportunities to further explore the harms associated with deciding to prescribe benzodiazepines or Z-drugs.

To ensure clinicians “do no harm,” it is important to maximize our use of routinely collected data. Future work could build on the current study by examining potential sex differences related to the use of benzodiazepines and the development of pneumonia. Sex differences should be evaluated for these drugs, given what is known about zolpidem: the US Food and Drug Administration issued a safety announcement indicating that zolpidem products are associated with a risk of next-morning impairment for activities that require complete mental alertness, including driving, particularly among women.12 As a result, a lower dose of the drug was recommended for women.12 To our knowledge, sex differences for Z-drugs have not been studied at the population level. If we understood the differences in the way that women and men respond to benzodiazepines and Z-drugs, we could better tailor our prescribing and monitoring practices to minimize harm when these medications are prescribed.

Taipale and colleagues have identified pneumonia as yet another adverse event associated with benzodiazepine and Z-drug use. Their study is a good reminder to clinicians to “first do no harm” when prescribing these drugs for frail older women and men with dementia. Nonpharmacologic approaches should be the starting point when managing neuropsychiatric symptoms in this patient population, which should help to limit inappropriate use of these drugs. For individuals already receiving benzodiazepines or Z-drugs, this study’s findings underline the importance of regularly reviewing medications and re-evaluating their need.

KEY POINTS
  • Medications used to manage neuropsychiatric symptoms in frail older individuals with dementia have concerning adverse events.

  • Nonpharmacologic approaches to management are preferred.

  • For individuals already receiving benzodiazepines or Z-drugs, it is important to review medications regularly.

Acknowledgement

Paula Rochon holds the Retired Teachers of Ontario / Les enseignantes et enseignants retraités de l’Ontario (RTO/ERO) Chair in Geriatric Medicine at the University of Toronto.

Footnotes

  • Competing interests: None declared.

  • Contributors: All of the authors contributed to the conception of the work. Paula Rochon drafted the manuscript. All of the authors revised it critically for important intellectual content, approved the final version to be published, and agreed to act as guarantors of the work.

  • This article was solicited and has not been peer reviewed.

References

  1. ↵
    1. Tamblyn R,
    2. Abrahamowicz M,
    3. du Berger R,
    4. et al
    . A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005;53:233–41.
    OpenUrlCrossRefPubMed
  2. ↵
    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–46.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Taipale H,
    2. Tolppanen AM,
    3. Koponen M,
    4. et al
    . Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. CMAJ 2017;189:E519–29.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Drug use among seniors on public drug programs in Canada, 2012. Ottawa: Canadian Institute for Health Information; 2014.
  5. ↵
    1. Wong SL,
    2. Gilmour H,
    3. Ramage-Morin PL
    . Health reports: Alzheimer’s disease and other dementias in Canada. Ottawa: Statistics Canada; modified 2016 May 18.
  6. ↵
    1. Morgan SG,
    2. Weymann D,
    3. Pratt B,
    4. et al
    . Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age Ageing 2016;45:535–42.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Bell CM,
    2. Fischer HD,
    3. Gill SS,
    4. et al
    . Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med 2007;22:1024–9.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Obiora E,
    2. Hubbard R,
    3. Sanders RD,
    4. et al
    . The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case–control and survival analysis in a population-based cohort. Thorax 2013;68:163–70.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Givens JL,
    2. Jones RN,
    3. Shaffer ML,
    4. et al
    . Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010;170:1102–7.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Vozoris NT
    . Do benzodiazepines contribute to respiratory problems? Expert Rev Respir Med 2014;8:661–3.
    OpenUrl
  11. ↵
    1. Vozoris NT,
    2. Fischer HD,
    3. Wang X,
    4. et al
    . Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2014;44:332–40.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) [safety announcement]. Silver Spring (MD): US Food and Drug Administration; 2013.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (14)
CMAJ
Vol. 189, Issue 14
10 Apr 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The harms of benzodiazepines for patients with dementia
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The harms of benzodiazepines for patients with dementia
Paula A. Rochon, Nicholas Vozoris, Sudeep S. Gill
CMAJ Apr 2017, 189 (14) E517-E518; DOI: 10.1503/cmaj.170193

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The harms of benzodiazepines for patients with dementia
Paula A. Rochon, Nicholas Vozoris, Sudeep S. Gill
CMAJ Apr 2017, 189 (14) E517-E518; DOI: 10.1503/cmaj.170193
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgement
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease
  • PubMed
  • Google Scholar

Cited By...

  • Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007
  • Google Scholar

More in this TOC Section

  • Time to dismantle systemic anti-Black racism in medicine in Canada
  • Preventing the introduction of SARS-CoV-2 into school settings
  • How should we move for health? The case for the 24-hour movement paradigm
Show more Commentary

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire